May 8, 1:02 AM EDT
Gilead targets $1B Yeztugo sales in 2026 while raising base business outlook to $29.4B-$29.8B
GILDGILD:CA
Earnings Call Insights: Gilead Sciences (GILD) Q1 2026 Management View CEO Daniel O'Day said the quarter “extended our consistent track record of commercial, clinical and financial execution,” adding that “our strong financial performance and increase in sales…